Networking at a Katconference |
Here are more details:
Pharma Law Academy
Scheduled to take place from 5 to 9 September 2022 on the premises of Downing College, University of Cambridge, the Pharma Law Academy is an intensive 5-day course.
Thanks to 35+ speakers and through 40+ sessions, this course will be providing participants with an understanding of key pharma law aspects - from the fundamentals through to advanced IP law, competition law, the regulatory frameworks, and wider compliance issues.
As stated, IPKat readers are entitled to a 15% discount using the VIP code FKW83455IPKE at checkout.
For further information and to register, please click here.
Competition Law in the Pharma Sector
Taking place at Le Châtelain Hotel in Brussels on 7 December 2022, this 1-day conference will allow participants to assess the legal risks currently facing the pharma industry and discover what new opportunities are available in this sector.
Participants will be also learning, among other things, about what the regulators and enforcers are doing, analyse the implications of the latest patent cases, where we are with the Illumina/Grail judgment, denigration cases, developments in pricing and distribution.
There will be a diverse range of experts, including regulators, top in-house counsel and specialised advisors.
As stated, IPKat readers are entitled to a 15% discount using the VIP code FKW83446IPKE at checkout.
For further information and to register, please click here.
InformaConnect pharma events return with IPKat readers’ discount
Reviewed by Eleonora Rosati
on
Monday, July 25, 2022
Rating:
No comments:
All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.
It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.
Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html